Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anna Strongin

Gastroenterology Rockville, MD Medical Doctor

NPI 1255621363 CMS profile 1390858

9711 Medical Center Dr Ste 308, Rockville, MD 20850

Open in the dashboard

General payments

$4,499

233 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Strongin of Rockville, MD is reported in the CMS Open Payments database as having received $4,499 across 233 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,494 70
2024 General $1,358 72
2023 General $773 42
2022 General $260 13
2021 General $80 4
2020 General $163 10
2019 General $371 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Strongin
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Anna Strongin were reported at $1,494. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Anna Strongin Gastroenterology median Middle half National median
2019 $371 $417 $126–$1,100 $163
2020 $163 $224 $74–$624 $114
2021 $80 $352 $106–$1,054 $132
2022 $260 $448 $129–$1,270 $149
2023 $773 $533 $150–$1,390 $160
2024 $1,358 $605 $160–$1,606 $164
2025 $1,494 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,149 56 payments
  2. Pfizer Inc. $526 26 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $491 28 payments
  4. Janssen Biotech, Inc. $423 24 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $280 16 payments
  6. Celgene Corporation $227 16 payments
  7. Madrigal Pharmaceuticals $143 6 payments
  8. Lilly USA, LLC $138 6 payments
  9. Regeneron Healthcare Solutions, Inc. $134 7 payments
  10. Intercept Pharmaceuticals, Inc. $122 7 payments
  11. Other $867 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,383 227 payments
  2. Education $116 6 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $563 32 payments
  2. RINVOQ $443 20 payments
  3. VELSIPITY $390 18 payments
  4. TREMFYA $342 20 payments
  5. XELJANZ $335 18 payments
  6. SKYRIZI $313 18 payments
  7. LINZESS $302 17 payments
  8. ZEPOSIA $227 16 payments
  9. CREON $178 10 payments
  10. ENTYVIO $160 8 payments
  11. Other $2,285 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

860

Median for Gastroenterology: 569

Drug cost

$71,723

Median for Gastroenterology: $104,976

Branded share of claims

24.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 36 $39,054
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 52 $8,901
Mesalamine Generic 11 $7,175
Omeprazole Generic 263 $3,490
Colestipol Hcl Generic 48 $2,799
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 44 $2,606
Famotidine Generic 153 $1,940
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 11 $1,734
Pantoprazole Sodium Generic 81 $1,284
Loperamide Loperamide Hcl Brand 16 $576

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$83,391

Medicare's payments for the services billed

Medicare patients

410

Average age 73

Services billed

824

307 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 47%
Diabetes 29%
Ischemic heart disease 28%
Osteoporosis 25%
Depression 17%
Chronic kidney disease 15%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $155
$155 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $124
$124 — —
RINVOQ
  • AbbVie, Inc. $106
$106 — —
TREMFYA
  • Janssen Biotech, Inc. $92
$92 — —
OMVOH
  • Lilly USA, LLC $75
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record